Potential marker of the pharmacodynamic effect of high doses of methotrexate — homocysteine

Authors

  • A. M. Strizhevskaya FGBI Russian Cancer Research Center of N.N. Blokhin RAMS
  • E. R. Senzhapova FGBI Russian Cancer Research Center of N.N. Blokhin RAMS
  • A. Z. Dzampaev FGBI Russian Cancer Research Center of N.N. Blokhin RAMS
  • V. N. Baykova FGBI Russian Cancer Research Center of N.N. Blokhin RAMS

Keywords:

Methotrexate, homocysteine, toxicity, osteosarcoma, child

Abstract

High-dose methotrexate blocks the metabolic pathways of conversion of homocysteine to methionine. As a result, homocysteine (hcy) accumulates in the blood. The aim of this study was to determine the relationship between changes in concentrations of hcy, mtx, and other criteria of toxicity in the key hours of therapeutic drug monitoring of mtx, as well as identifying the possibility of using hcy as a marker of toxicity and effectiveness of high-dose mtx therapy. The study includes data on 246 children with osteosarcoma of different localisation.

Downloads

Published

2014-06-12

Issue

Section

Original research

How to Cite

[1]
2014. Potential marker of the pharmacodynamic effect of high doses of methotrexate — homocysteine. Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya (Pathological physiology and experimental therapy). 58, 2 (Jun. 2014), 40–44.